Literature DB >> 8641323

Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts.

J W de Vos1, P J Geerlings, W van den Brink, J G Ufkes, H van Wilgenburg.   

Abstract

In a closed metabolic ward the pharmacokinetics of methadone and its primary metabolite (EDDP) were studied in 20 long-term opiate addicts. After administration of the daily oral dose of methadone HCl (mean 60 mg, range 10-225 mg) blood samples were taken and analysed, using a newly developed high-performance liquid chromatography (HPLC) method. The steady-state plasma concentrations of the 20 subjects varied from 65-630 ng x ml(-1) and from 5 to 55 ng x ml(-1), whereas the peak concentrations were 124-1255 ng x ml(-1) and 10-301 ng x ml(-1) for methadone and the AUC(0-24 h) for EDDP varied from 5.9 to 44.6, indicating interindividual differences in metabolic activity. In 19 out of 20 subjects the pharmacokinetics of methadone are best described using a two-compartment model. The mean body clearance was 1.64 ml x min(-1) x kg(-1), whereas the mean elimination rate constant (beta) and plasma half-life (t1/2beta) were 0.026 x h(-1) (range 0.013-0.053 x h(-1)) and 31.2 h (range 13-53 h), respectively. Differences of gender were also found. A poor correlation was found between the methadone dose and the steady-state level. A much better correlation was found between the normalized steady-state level and the body clearance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8641323     DOI: 10.1007/bf00194951

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  The use of plasma levels to optimize methadone maintenance treatment.

Authors:  N Loimer; R Schmid
Journal:  Drug Alcohol Depend       Date:  1992-08       Impact factor: 4.492

2.  MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring.

Authors:  J H Proost; D K Meijer
Journal:  Comput Biol Med       Date:  1992-05       Impact factor: 4.589

3.  Urinary metabolites of dl-methadone in maintenance subjects.

Authors:  H R Sullivan; S L Due
Journal:  J Med Chem       Date:  1973-08       Impact factor: 7.446

4.  Steady-state pharmacokinetics of methadone in opioid addicts.

Authors:  K Wolff; A W Hay; D Raistrick; R Calvert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Disposition of methadone in methadone maintenance.

Authors:  E Anggård; L M Gunne; J Homstrand; R E McMahon; C G Sandberg; H R Sullivan
Journal:  Clin Pharmacol Ther       Date:  1975-03       Impact factor: 6.875

6.  Effects of liver disease on urinary excretion of methadone and metabolites in maintenance patients: quantitation by direct probe chemical ionization mass spectrometry.

Authors:  M J Kreek; F A Bencsath; F H Field
Journal:  Biomed Mass Spectrom       Date:  1980-09

7.  A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.

Authors:  V P DOLE; M NYSWANDER
Journal:  JAMA       Date:  1965-08-23       Impact factor: 56.272

8.  Estimation of methadone clearance: application in the management of cancer pain.

Authors:  J L Plummer; G K Gourlay; D A Cherry; M J Cousins
Journal:  Pain       Date:  1988-06       Impact factor: 6.961

9.  Pharmacokinetics of continuous intravenous infusion of methadone in the early post-burn period.

Authors:  D D Denson; R R Concilus; G Warden; P P Raj
Journal:  J Clin Pharmacol       Date:  1990-01       Impact factor: 3.126

10.  Methadone concentrations in plasma and their relationship to drug dosage.

Authors:  K Wolff; M Sanderson; A W Hay; D Raistrick
Journal:  Clin Chem       Date:  1991-02       Impact factor: 8.327

View more
  24 in total

1.  Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.

Authors:  David J R Foster; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

2.  Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).

Authors:  Evan D Kharasch; Pamela Sheffels Bedynek; Christine Hoffer; Alysa Walker; Dale Whittington
Journal:  Anesthesiology       Date:  2012-02       Impact factor: 7.892

3.  Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model.

Authors:  Feng Yang; Xianping Tong; D Gail McCarver; Ronald N Hines; Daniel A Beard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-07       Impact factor: 2.745

Review 4.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

5.  Determination and pharmacokinetics of dextromoramide in methadone maintenance therapy.

Authors:  J G Ufkes; J W de Vos; G H van Brussel
Journal:  Pharm World Sci       Date:  1998-04

Review 6.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

7.  Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.

Authors:  Evan D Kharasch; Karen J Regina; Jane Blood; Christina Friedel
Journal:  Anesthesiology       Date:  2015-11       Impact factor: 7.892

8.  The opioid oxycodone use-dependently inhibits the cardiac sodium channel NaV 1.5.

Authors:  Jannis E Meents; Krisztina Juhasz; Sonja Stölzle-Feix; Vera Peuckmann-Post; Roman Rolke; Angelika Lampert
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

9.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  The impact of cocaine and heroin on the placental transfer of methadone.

Authors:  Antoine Malek; Cristina Obrist; Silvana Wenzinger; Ursula von Mandach
Journal:  Reprod Biol Endocrinol       Date:  2009-06-11       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.